(Q37847070)

24 August 2017

1 reference

title

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor (English)

1 reference

24 August 2017

1 reference

Edgardo S Santos

1

1 reference

24 August 2017

Jorge E Gomez

series ordinal

2

1 reference

24 August 2017

Luis E Raez

series ordinal

3

1 reference

24 August 2017

language of work or name

1 reference

25 February 2011

1 reference

Investigational New Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

30

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

1261-1269

1 reference

Angiogenesis in cancer and other diseases

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Vascular endothelial growth factor: basic science and clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

The potential of antiangiogenic therapy in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

What brings pericytes to tumor vessels?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Platelet-derived growth factor (PDGF) and glial tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Advances in target therapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9644-2

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

21 January 2018

1 reference

12 December 2020

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma

1 reference

12 December 2020

Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR)

1 reference

12 December 2020

Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow

1 reference

12 December 2020

Toxicities of antiangiogenic therapy in non-small-cell lung cancer.

1 reference

12 December 2020

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

1 reference

12 December 2020

Antiangiogenic agents and vascular disrupting agents for the treatment of lung cancer: a review

1 reference

12 December 2020

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

1 reference

12 December 2020

Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers

1 reference

12 December 2020

10.1007/S10637-011-9644-2

Identifiers

DOI

1 reference

24 August 2017

1 reference